Lantern Pharma's LP-284 Shows Promise in Treating Refractory Lymphomas

Lantern Pharma (NASDAQ: LTRN) has reported a significant breakthrough in its Phase 1 trial of LP-284, a next-generation acylfulvene, with a complete metabolic response observed in a heavily pretreated patient with aggressive Grade 3 non-germinal center B-cell DLBCL. This marks the first such response for LP-284, developed using Lantern’s RADR(R) AI platform, showcasing its potential as a paradigm-shifting therapy in the $4 billion global B-cell cancer market. The patient, who had failed three prior regimens including CAR-T and bispecific antibody therapy, responded after just two cycles of LP-284. This outcome underscores the synthetic lethal mechanism of LP-284 and supports its accelerated development. Lantern Pharma, leveraging its AI and machine learning platform RADR(R), is transforming oncology drug discovery, significantly reducing the time and cost associated with bringing new therapies to market.

For more details, visit the full press release at https://ibn.fm/TCGHH. Lantern Pharma's innovative approach, utilizing over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms, has enabled the rapid advancement of its drug programs from initial AI insights to first-in-human clinical trials in just 2-3 years at approximately $2.5 million per program. This achievement highlights the company's role in revolutionizing cancer treatment through technology.